Gene Editing Reveals Interaction between Antimicrobial Peptides and Pathogens
|
By LabMedica International staff writers Posted on 13 Mar 2019 |

Image: Fruit flies (Drosophila) with mutated antimicrobial peptides (red eyes) let bacteria (green fluorescence) grow out of control, while wild-type flies (with normal antimicrobial peptides) suppress the infection (Photo courtesy of Dr. Mark Austin Hanson, École Polytechnique Fédérale de Lausanne).
The genome editing tool CRISPR/Cas9 was used to delete the genes coding for inducible antimicrobial peptides (AMPs) in fruit flies (Drosophila), which revealed the highly specific interaction between AMPs and pathogens in an in vivo model system.
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
Antimicrobial peptides are a unique and diverse group of molecules, which are divided into subgroups on the basis of their amino acid composition and structure. Antimicrobial peptides are generally composed of between 12 and 50 amino acids. These peptides include two or more positively charged residues provided by arginine, lysine or, in acidic environments, histidine, and a large proportion (generally more than 50%) of hydrophobic residues. AMPs can possess multiple activities including anti-gram-positive bacterial, anti-gram-negative bacterial, anti-fungal, anti-viral, anti-parasitic, and anti-cancer activities. The amphipathicity of the antimicrobial peptides allows them to partition into the membrane lipid bilayer of the pathogen. The ability to associate with membranes is a definitive feature of antimicrobial peptides, and they have a variety of antimicrobial activities ranging from membrane permeabilization to action on a range of cytoplasmic targets.
Investigators at École Polytechnique Fédérale de Lausanne (Switzerland) utilized CRISPR gene editing to delete all known immune inducible AMPs of Drosophila, namely: four attacins, four cecropins, two diptericins, drosocin, drosomycin, metchnikowin, and defensin. Using individual and multiple knockouts, including flies lacking all 14 AMP genes, they characterized the in vivo function of individual and groups of AMPs against diverse bacterial and fungal pathogens.
Results published in the February 26, 2019, online edition of the journal eLife revealed that Drosophila AMPs acted primarily against Gram-negative bacteria and fungi, contributing either additively or synergistically. In addition, the investigators found that certain AMPs could be incredibly specific in defending against certain infections (e.g., the AMP diptericin against the pathogen Providencia rettgeri).
“What is really exciting is that these results will help us understand how our own AMPs might help fight infection,” said first author Dr. Mark Austin Hanson, a doctoral assistant at École Polytechnique Fédérale de Lausanne. “It could be that some people have a defective copy of a specific AMP needed to prevent a common infection - as an example, uropathogenic E. coli - and so they are at higher risk. Fighting infection is great, but learning how to prevent it in the first place is the ideal of medicine. That is what these AMPs do: they prevent infection before it ever settles in.”
Furthermore, said Dr. Hanson, “Studying how the fly’s AMPs work can also help us manage economically important insects, whether it be protecting bumblebees or preventing mosquitoes from spreading disease.”
Related Links:
École Polytechnique Fédérale de Lausanne
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
Antimicrobial peptides are a unique and diverse group of molecules, which are divided into subgroups on the basis of their amino acid composition and structure. Antimicrobial peptides are generally composed of between 12 and 50 amino acids. These peptides include two or more positively charged residues provided by arginine, lysine or, in acidic environments, histidine, and a large proportion (generally more than 50%) of hydrophobic residues. AMPs can possess multiple activities including anti-gram-positive bacterial, anti-gram-negative bacterial, anti-fungal, anti-viral, anti-parasitic, and anti-cancer activities. The amphipathicity of the antimicrobial peptides allows them to partition into the membrane lipid bilayer of the pathogen. The ability to associate with membranes is a definitive feature of antimicrobial peptides, and they have a variety of antimicrobial activities ranging from membrane permeabilization to action on a range of cytoplasmic targets.
Investigators at École Polytechnique Fédérale de Lausanne (Switzerland) utilized CRISPR gene editing to delete all known immune inducible AMPs of Drosophila, namely: four attacins, four cecropins, two diptericins, drosocin, drosomycin, metchnikowin, and defensin. Using individual and multiple knockouts, including flies lacking all 14 AMP genes, they characterized the in vivo function of individual and groups of AMPs against diverse bacterial and fungal pathogens.
Results published in the February 26, 2019, online edition of the journal eLife revealed that Drosophila AMPs acted primarily against Gram-negative bacteria and fungi, contributing either additively or synergistically. In addition, the investigators found that certain AMPs could be incredibly specific in defending against certain infections (e.g., the AMP diptericin against the pathogen Providencia rettgeri).
“What is really exciting is that these results will help us understand how our own AMPs might help fight infection,” said first author Dr. Mark Austin Hanson, a doctoral assistant at École Polytechnique Fédérale de Lausanne. “It could be that some people have a defective copy of a specific AMP needed to prevent a common infection - as an example, uropathogenic E. coli - and so they are at higher risk. Fighting infection is great, but learning how to prevent it in the first place is the ideal of medicine. That is what these AMPs do: they prevent infection before it ever settles in.”
Furthermore, said Dr. Hanson, “Studying how the fly’s AMPs work can also help us manage economically important insects, whether it be protecting bumblebees or preventing mosquitoes from spreading disease.”
Related Links:
École Polytechnique Fédérale de Lausanne
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








